Sab biotherapeutics announces commencement of the human phase 1 clinical trial with sab-142, a potential disease-modifying treatment for type 1 diabetes

First subject has been dosed in the first-in-man phase 1 clinical study of sab-142, the first fully-human anti-thymocyte immunoglobulin (atg)

SABS Ratings Summary

SABS Quant Ranking